|
Gender
|
|
|
|
0.106 |
| Male N, (%) |
260 (57) |
187 (55) |
73 (64) |
|
| Female N, (%) |
196 (43) |
154 (45) |
42 (36) |
|
|
Age, mean, SD (years)
|
62.56 ± 13.5 |
61,5 ± 13.2 |
65,7 ± 14 |
0.004
|
|
Onset of symptoms to admission, mean, SD ( days)
|
8.5 ± 4.12 |
8.8 ± 4.12 |
7.9 ± 4.11 |
0.022
|
|
BMI, kg/m
2
, SD
|
29.3 ± 5 |
29.33 ± 5.45 |
29.06 ± 5.88 |
0.672 |
|
Chronic concomitant diseases, N (%)
|
322 (70.8) |
236 (69.2) |
86 (75.4) |
0.256 |
| Hypertension, N (%) |
198 (43.4) |
146 (42.8) |
52 (45.6) |
0.653 |
| Diabetes, N (%) |
171 (37.5) |
126 (37) |
45 (39.5) |
0.676 |
| Dyslipidemia, N (%) |
72 (15.8) |
51 (15) |
21 (18.4) |
0.401 |
| Coronary artery disease, N (%) |
45 (9.9) |
35 (10.3) |
10 (8.8) |
0.626 |
| Obesity, N (%) |
203 (40) |
157 (46) |
46 (40) |
0.298 |
| COPD, N (%) |
23 (5) |
16 (4.7) |
7 (6.1) |
0.554 |
|
Symptoms
|
| Asthenia, N (%) |
324 (71) |
238 (70.8) |
86 (74.8) |
0.308 |
| Fever, N (%) |
286 (63) |
211 (62.6) |
75 (65.2) |
0.522 |
| Myalgia, N (%) |
221 (48.5) |
179 (53.3) |
42 (36.5) |
0.003
|
| Dyspnea, N (%) |
305 (67) |
226 (67.3) |
79 (68.7) |
0.633 |
| Cough, N (%) |
229 (50) |
169 (50.3) |
60 (52.2) |
0.628 |
| Nasal symptoms , N (%) |
25 (5.5) |
14 (4.2) |
11 (9.6) |
0.026
|
|
Peripheral oxygen saturation in room air, %, SD
|
88 ± 4.24 |
88.8 ± 4 |
87.1 ± 4.5 |
<0.001
|
|
CT findings
|
| Extent of lesions > 50%, N (%) |
129 (31.4) |
86 (25,6) |
43 (37) |
0.021
|
| Bilateral distribution, N (%) |
386 (98.2) |
287 (98.6) |
99 (97) |
0.42 |
| Ground-glass opacity, N (%) |
385 (96.7) |
283 (93) |
102 (95) |
0.568 |
| Consolidations, N (%) |
276 (70.6) |
202 (69.7) |
74 (73.3) |
0.662 |
| Pleural effusion, N (%) |
27 (6.9) |
17 (6) |
10 (9) |
0.183 |
| Pericardial effusion, N (%) |
40 (10.2) |
23 (8) |
17 (16) |
0.013
|
|
Outcome
|
|
|
|
|
| Transfer to intensive care unit, N (%) |
81 (16.6) |
11 (3.2) |
70 (60.9) |
<0.001
|
| Deaths in the COVID-19 unit, N (%) |
22 (4.8) |
1 (0.3) |
21 (1.3) |
<0.001
|
